Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

12 Aug 2013 07:00

RNS Number : 4204L
ReNeuron Group plc
12 August 2013
Β 

Β 

DTR3

Β 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/ PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

Β 

All relevant boxes should be completed in block capital letters.

Β 

1.

Name of the issuer

Β 

ReNeuron Group plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2RΝΎ or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006

Β 

(i)

Β 

3.

Name of person discharging managerial responsibilities/director

Β 

Michael Hunt

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3

and identify the connected person

Β 

Director named in 3.

Β 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1

Β 

Interest of person named in 3

Β 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

Β 

Ordinary Shares

Β 

Β 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

Β 

Person named in 3

Β 

8.

State the nature of the transaction

Β 

Placing of Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired

Β 

Acquisition of 800,000 Ordinary Shares

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

Β 

0.045%

Β 

11.

Number of shares, debentures or financial instruments relating to shares disposed

Β 

Β 

Β 

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

Β 

Β 

Β 

13.

Price per share or value of transaction

Β 

2.5 pence per Ordinary Share

Β 

14.

Date and place of transaction

Β 

9 August 2013

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

Β 

Michael Hunt is interested in a total of 1,253,023 Ordinary Shares in the Company representing approximately 0.070% of issued Ordinary Shares.

Β 

16.

Date issuer informed of transaction

Β 

9 August 2013

Β 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

Β 

17.

Date of grant

Β 

Β 

18.

Period during which or date on which it can be exercised

Β 

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

Β 

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

Β 

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

Β 

See table of options held by Michael Hunt below:

Β 

Β 

Β 

Number of options

Exercise Price

End of Exercise Period

806,370

5.06p

July 2014

971,690

5.06p

July 2014

1,975,621

12.65p

August 2015

493,359

5.07p

August 2016

493,359

7.6p

August 2016

860,328

12.2p

August 2017

860,328

21.79p

August 2017

1,442,887

1.0p

August 2020

1,772,728

1.0p

August 2019

2,071,066

1.0p

August 2020

2,916,667

1.0p

August 2021

3,181,818

1.0p

September 2022

17,846,221

24.

Name of contact and telephone number for queries

Β 

Pat Huggins, Reneuron Group Plc

+44 (0)1483 302560

Β 

Β 

Name of authorised official of issuer responsible for making notification:

Β 

Patrick Huggins, Head of Finance and Company Secretary

Β 

Date of notification: 9 August 2013

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSLLFEETFIAIIV
Date   Source Headline
18th Nov 20217:00 amRNSNotice of Results
1st Nov 20217:00 amRNSTotal Voting Rights
26th Oct 20213:09 pmRNSDirector exit arrangements
26th Oct 20217:00 amRNSCollaboration agreement with UCL
21st Oct 20217:00 amRNSDirector Share Purchase
20th Oct 20217:00 amRNSDirector/PDMR Interest in Share Options
18th Oct 20217:00 amRNSFurther changes in the Board of Directors
18th Oct 20217:00 amRNSFirst subject treated at Oxford Eye Hospital
12th Oct 20212:05 pmRNSSecond Price Monitoring Extn
12th Oct 20212:01 pmRNSPrice Monitoring Extension
11th Oct 20214:40 pmRNSSecond Price Monitoring Extn
11th Oct 20214:35 pmRNSPrice Monitoring Extension
11th Oct 20212:06 pmRNSSecond Price Monitoring Extn
11th Oct 20212:00 pmRNSPrice Monitoring Extension
11th Oct 202111:05 amRNSSecond Price Monitoring Extn
11th Oct 202111:00 amRNSPrice Monitoring Extension
11th Oct 20219:05 amRNSSecond Price Monitoring Extn
11th Oct 20219:00 amRNSPrice Monitoring Extension
11th Oct 20217:00 amRNSPositive data generated in exosome collaboration
1st Oct 20217:00 amRNSRegulatory approval for continuation of RP trial
16th Sep 20214:26 pmRNSResult of AGM
2nd Sep 202112:00 pmRNSBlock Listing Review, Application and TVR
16th Aug 20212:20 pmRNSPosting of AR and Accounts and Notice of AGM
6th Aug 20217:00 amRNSDirectorate Change
14th Jul 20217:00 amRNSBoard Change
8th Jul 20217:00 amRNSPreliminary Results for the year ended 31 March 21
2nd Jul 20211:00 pmRNSNotice of Results
2nd Jul 20217:00 amRNSNotice of Results
1st Jul 20217:00 amRNSDirectorate Change
1st Jul 20217:00 amRNSTotal Voting Rights
18th Jun 202110:48 amRNSHolding(s) in Company
9th Jun 20214:36 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension
9th Jun 202111:55 amRNSUpdate for hRPC therapy candidate study
7th Jun 20215:25 pmRNSHolding(s) in Company
20th May 20217:00 amRNSAppointment of Chief Scientific Officer
4th May 20217:00 amRNSTotal Voting Rights
29th Apr 20217:00 amRNSInitiation of research by Allenby Capital
6th Apr 20217:00 amRNSVirtual conference attendance and presentations
30th Mar 20217:00 amRNSHolding(s) in Company
19th Mar 20217:00 amRNSExosome platform update
16th Mar 20214:05 pmRNSHolding(s) in Company
16th Mar 202110:57 amRNSHolding(s) in Company
16th Mar 20217:00 amRNSHolding(s) in Company
12th Mar 20217:00 amRNSDirectorate Change
1st Mar 20217:00 amRNSBlock Listing Review and Total Voting Rights
25th Feb 20217:01 amRNSInvestor presentations
25th Feb 20217:00 amRNSAppointment of Joint Broker
11th Feb 20217:00 amRNSDirector/PDMR Interest in Shares and Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.